Shares of Certara, Inc. (NASDAQ:CERT – Get Free Report) have earned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat reports. Six ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Certara (CERT – Research Report), with a price ...

During a speech at the White House on Tuesday, Ellison emphasized AI's ability to detect cancer early through blood tests and its crucial role in creating individualized vaccines rapidly. This ...

Stock analysts at William Blair increased their FY2024 earnings per share estimates for shares of Certara in a report issued on Wednesday, January 15th. William Blair analyst M. Smock now anticipates ...

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Buy rating on Certara (CERT – Research Report), with a price target of $15.00. Discover outperforming ...

Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of ...

Certara reports 2024 revenue of $384.4 million, bookings of $445.3 million, and confirms adjusted EBITDA guidance of $120-$124 million. Certara, Inc. reported preliminary financial results for ...

RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full ...